Ancillare, the industry leader in Clinical Trial Ancillary Supply Chain (CTASC™), obtains authorization to distribute medical devices in Canada.

Horsham, Pa. — January 14th, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, announced it obtained its Medical Device Establishment License (MDEL) in August of 2020 and is now actively importing medical devices in support of Phase I-IV clinical trials.

The MDEL, which allows for the import and sale of medical devices, will serve to strengthen Ancillare’s global distribution network.

Ancillare applied for the MDEL in response to the Canada Border Services Agency’s (CBSA) Single Window Initiative, which enacted new licensing requirements for importers of medical devices and other goods under Health Canada jurisdiction. The license demonstrates compliance to Health Canada’s Medical Device Regulation (MDR), and gives Ancillare the ability to import registered medical devices for clinical use in Canada.

“With an MDEL, Ancillare can better support our Sponsors by facilitating medical device imports,” said Dr. Joanne Santomauro, Chief Executive Officer. “Maintaining regulatory knowledge and compliance is among our key value offerings, and represents just one example of our ongoing efforts to strengthen Ancillare’s global distribution capabilities.”

To learn more about Ancillare’s service offering, including global distribution and regulatory support, visit Ancillare.com/Services.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Philadelphia-based optometrist Dr. Georgia Crozier joins Ancillare, leader in Clinical Trial Ancillary Supply Chain™, to consult on clinical trial planning.

Horsham, Pa. — November 12th, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it has appointed Georgia Crozier, OD, MS as a Medical Director to serve on its growing Clinical Development Team.

Dr. Crozier will leverage years of experience at multiple clinical sites to serve as a Subject Matter Expert for clinical trial planning and execution. Working directly with Ancillare’s internal teams and with Sponsors, Dr. Crozier will consult on matters of compliance for robust CTASC design.

An optometrist who has worked at a number of clinical sites, Dr. Crozier brings over 35 years of experience in her field —as a clinical investigator, medical consultant, and lecturer. She is a graduate of Pennsylvania College of Optometry at Salus University, and currently serves as the Director of the Moore Eye Institute Vision Rehabilitation Center.

“We are thrilled to bring on Dr. Crozier as a Medical Director,” said Dr. Joanne Santomauro, Chief Executive Officer. “Expanding our Clinical Development Team will further streamline the selection of ancillary supplies that meet increasingly demanding protocols and ever-changing global regulations. Ophthalmologic studies tend to be highly specialized with a broad range of supply and equipment needs, and we are excited to have Dr. Crozier’s expertise in-house for our Sponsors and clients.”

Dr. Crozier will serve as Medical Director alongside Dr. John Fitzgerald, who was recently appointed to the same role. The two physicians will work as a team and leverage their individual areas of expertise to better serve Ancillare’s Sponsors.

To read full biographies of Ancillare’s Medical Directors and learn more about the company’s Subject Matter Experts, visit https://www.ancillare.com/about/#leadership.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare, the world leader in Clinical Trial Ancillary Supply Chain (CTASC™), announced that its new Distribution Facility will open December 1.

Horsham, Pa. — November 9th, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it will open a new Distribution Facility in the Netherlands on December 1, 2020.

Ancillare currently holds over a dozen strategic depots to manage the flow of supplies to clinical trial sites around the globe. In addition to Ancillary Supply Chain storage and distribution, the new facility will be home to Ancillare’s European headquarters.

“We are proud to expand our global footprint through our new Netherlands facility,” said Dr. Joanne Santomauro, Chief Executive Officer. “This strategic distribution hub will allow for more streamlined Clinical Trial Ancillary Supply Chains across Europe, and will help us continue reaching more trial sites, and patients, around the world.”

Over the past several months, Ancillare’s global operations teams have worked diligently to ensure that the new facility opens successfully on December 1. The company has obtained all necessary licenses and approvals for business operations in the EU, and is working to ensure a seamless transition for Sponsors.

To learn more about Ancillare’s Global Distribution Network, visit Ancillare.com/About.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

John Fitzgerald, DO, FACOG, joins Ancillare as Medical Director to lend clinical expertise to Clinical Trial Ancillary Supply Chains™.

Horsham, Pa. — October 29th, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it has appointed John Fitzgerald, DO, FACOG as Medical Director to serve on its growing Clinical Development Team.

Dr. Fitzgerald will consult with Ancillare’s cross-functional teams to ensure compliant ancillary supply chains during the clinical study design and execution phases and will also collaborate directly with trial Sponsors to provide his clinical expertise.

A practicing obstetrician and gynecologist in the Philadelphia area for over three decades, Dr. Fitzgerald also serves as the Associate Director/Associate Professor for the Physician Assistant Program at Salus University. He has published a number of research articles on a variety of women’s health topics as well as a lead investigator for the National HPV Study.

“We are pleased to bring on Dr. Fitzgerald as a Medical Director,” said Dr. Joanne Santomauro, Chief Executive Officer. “For the past fifteen years, Ancillare has solved countless complex supply challenges for our Sponsors. Dr. Fitzgerald and the entire Clinical Development Team are critical to expanding Ancillare’s value offering through their specialized clinical knowledge and experience.”

To read full biographies of Ancillare’s Medical Directors and learn more about the company’s Subject Matter Experts, visit https://www.ancillare.com/about/#leadership.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and United Kingdom, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare, the Industry leader in Clinical Trial Ancillary Supply Chain™, captures several multi-million dollar contracts during the COVID-19 pandemic.

HORSHAM, Pa. — September 15, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it has closed several multi-million dollar three-to-five year contracts with major global pharmaceutical companies.

The series of large wins marks another step toward Ancillare’s diversification goals, which aim to grow its offerings worldwide. Earlier this year, the company announced it had secured a multi-million dollar debt financing deal with Fulton Bank, which enabled progress toward enhancing its technology services, expanding to new verticals, and beginning to execute a long-term acquisitions strategy.

“This milestone reflects Ancillare’s orientation toward growth and creates further opportunities to expand our services,” said Dr. Joanne Santomauro, Chief Executive Officer. “In tandem with the long-term, structured capital we’ve secured, these new contracts support our commitment to deliver innovation across the supply chain and throughout the entire clinical trial space.”

The new business wins add to Ancillare’s extensive portfolio, which now includes fifteen ongoing COVID-19 trials for which the company is providing CTASC management.

“With the urgency the pandemic has imposed on the pharmaceutical world, clinical trial Sponsors need reliable supply and equipment solutions,” Santomauro added. “We attribute our recent successes to the fact that we are not just another supplier, but instead a true partner with a consultative and forward-thinking approach. These wins are a testament to Ancillare’s end-to-end consultative approach to CTASC.”

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and United Kingdom, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com